2-deoxy-D-galactose | 85115-07-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-deoxy-D-galactose
• 英文别名: 2-Desoxy-L-galaktose；L-lyxo-2-deoxy-hexose；2-Deoxy-d-allose；(3S,4S,5S)-3,4,5,6-tetrahydroxyhexanal
• CAS: 85115-07-7
• 化学式: C₆H₁₂O₅
• 分子量: 164.158
• InChiKey: VRYALKFFQXWPIH-ZLUOBGJFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-deoxy-D-galactose 在 transaminase biocatalyst ATA₂₅₆ 、 异丙胺 作用下， 反应 48.0h， 以22%的产率得到
  参考文献：
  名称：

  使用胺转氨酶生物催化剂将醛糖转化为有价值的ω-氨基醇

  摘要：

  使用关键的生物催化步骤将容易获得的单糖转化为高价值的氨基醇是制备这些手性合成子的有吸引力的策略。在这里，我们报告了一个以前未描述的单糖直接胺化的例子，该糖主要使用胺转氨酶生物催化剂在平衡状态下以环状形式存在，以中等到高的转化率和分离的产率提供了一组氨基醇。最初使用邻苯二甲撑二胺的最新开发的高通量比色筛查方法来鉴定对环糖具有这种活性的胺转氨酶，并使用异丙胺成功地扩大了反应规模。

  DOI：

  10.1021/acscatal.8b04564
• 作为产物：
  描述：

  (E)-3-(4,5-dihydroisoxazol-5-yl)allyl acetate 在 Pd-BaSO₄ 四氧化锇 、 氢气 、 双氧水 作用下， 以 甲醇 、 水 、 丙酮 为溶剂， 反应 2.0h， 生成 2-deoxy-D-galactose
  参考文献：
  名称：

  有机合成中的硝酸甲硅烷基酯和一氧化氮。d，l-脱氧糖的新途径。使用氧化铝作为固相碱生成

  摘要：

  为脱氧醛糖和脱氧酮糖的三步合成开发了新的方法：1.选择性地将亚硝酸甲硅烷基酯或氧化亚氮区域选择性地加成到二烯中。2.双键的立体特异性羟基化。3.通过催化还原2-异恶唑啉使醛醇部分不掩盖。描述了D，L-脱氧核糖，D，L-油糖，D，L-指氧糖，D，L-2-脱氧半乳糖，1，3-二脱氧果糖，3-脱氧果糖的合成。引入碱性氧化铝作为固相碱，用于由醛肟和烯烃一步合成2-异恶唑啉。化合物的X射线衍射研究验证了立体化学分配。

  DOI：

  10.1016/s0040-4020(01)91358-4

文献信息

• Lactone derivative and its manufacturing method
  申请人：Kamiya Masayuki

  公开号：US20060058536A1

  公开（公告）日：2006-03-16

  A novel lactone derivative that is expressed by the following structural formula (I).

  一种新的内酯衍生物，其化学结构式(I)如下所示。
• Compositions and methods for treating cancer
  申请人：Tidmarsh George

  公开号：US20060142207A1

  公开（公告）日：2006-06-29

  Methods and compositions are provided for the treatment of cancer that take advantage of the increased uptake of glucose-anti-neoplastic agent conjugates in cancer cells relative to normal cells.

  本发明提供了一种治疗癌症的方法和组合物，利用了癌细胞相对于正常细胞对葡萄糖-抗肿瘤药物结合物的摄取增加的特性。
• Ellipticine derivative and production process thereof
  申请人：SUNTORY LIMITED

  公开号：EP0173462A2

  公开（公告）日：1986-03-05

  An ellipticine derivative having the general formula: wherein R represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 4 carbon atoms, or an acyloxy group having 2 to 7 carbon atoms; R2 represents an aldose residue, a deoxyaldose residue, an N-acylaminoaldose residue having a substituted acyl group with 2 to 4 carbon atoms bonded to the N atom, an aldohexuronic amide residue, and aldohexuronic acid residue, an acylated aldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated deoxyaldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated N-acylaminoaldose residue having an amino group substituted with an acyl group with 2 to 4carbon atoms and having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic amide residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic acid residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic acid ester residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an arylalkylated aldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated deoxyaldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 7 to 8 carbon atoms, an arylalkylated N-acylaminoaldose residue having an amino group with an acyl group with 2 to 4 carbon atoms and having, substituted for the hydrogen of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic amide residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic acid residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic acid ester residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms; and R3 represents a hydrogen atom, a linear, branched, cyclic, or cyclic-linear alkyl group having 1 to 5 carbon atoms; X0 represents a pharmaceutically acceptable inorganic or organic acid anion; and the bond represented by N⊕ - R2 in the general formula (I) represents a glycoside bond between a nitrogen atom in the 2-position of the ellipticine and a carbon atom in the 1-position of the sugar. These ellipticine derivatives have a strong antineoplastic or antitumor activity and, therefore, are expected to be effective as an antineoplastic or antitumor agent.

  一种具有通式的鞣花碱衍生物： 其中 R 代表氢原子、羟基、具有 1 至 4 个碳原子的烷氧基或具有 2 至 7 个碳原子的酰氧基； R2 代表醛糖残基、脱氧醛糖残基、N-酰氨基醛糖残基（其 N 原子上键有 2 至 4 个碳原子的取代酰基）、醛缩脲酰胺残基、醛缩脲酸残基、酰化醛糖残基（其糖羟基的氢原子被取代）、一种酰化脱醛糖残基，其糖羟基的氢原子被 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代、酰化的 N-酰氨基醛糖残基，其氨基被 2 至 4 个碳原子的酰基取代，并具有 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代糖羟基的氢原子；酰化的醛缩酰胺残基，其具有一种酰化的醛缩己脲酰胺残基，其糖的羟基的氢原子被 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代、酰化醛缩醛酸酯残基，其糖羟基的氢原子被 2 至 4 个碳原子的烷基酰基或 7 至 9 个碳原子的芳基酰基取代、芳烷基化脱醛糖残基，其糖的羟基的氢原子被 7 至 8 个碳原子的烷酰基取代；芳烷基化 N-酰氨基醛糖残基，其氨基带有 2 至 4 个碳原子的酰基，并具有一种芳烷基化的醛缩脲酰胺残基，其氨基具有 2 至 4 个碳原子的酰基，并具有 7 至 8 个碳原子的芳烷基取代糖的羟基的氢原子、一种芳烷基化的醛缩脲酸酯残基，其糖的羟基的氢原子被具有 7 至 8 个碳原子的芳烷基取代；和 R3 代表氢原子、具有 1 至 5 个碳原子的直链、支链、环状或环状直链烷基； X0 代表药学上可接受的无机或有机酸阴离子；以及 通式（I）中 N⊕ - R2 所代表的键代表鞣花碱 2 位上的氮原子与糖 1 位上的碳原子之间的糖苷键。这些鞣花碱衍生物具有很强的抗肿瘤或抗肿瘤活性，因此有望成为有效的抗肿瘤或抗肿瘤药物。
• METHOD OF ALPHA-SELECTIVE GLYCOSYLATION
  申请人：Japan Science and Technology Agency

  公开号：EP1626053B1

  公开（公告）日：2011-07-06
• METHOD FOR IMPROVING THE FEED CONVERSION EFFICIENCY OF MEAT-PRODUCING ANIMALS BY ORAL ADMINISTRATION OF 2-DEOXY-D-HEXOSE
  申请人：EASTMAN KODAK COMPANY (a New Jersey corporation)

  公开号：EP0390783A1

  公开（公告）日：1990-10-10